NOVAVAX INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
NOVAVAX INC (NVAX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$22.75 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-08
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $2.53M, a 86.67% decline year-over-year.
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$25.28M.
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $85.91M, a 798.68% increase year-over-year.
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $92.57M.
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $28.02M.
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$21.27M.
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$129.83M, a 892.05% decline from fiscal 2013.
- NOVAVAX INC net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was $16.39M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | $2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$22.75M 10-Q · filed 2017-08-08 | $63.15M derived: sum of 3 quarters · filed 2017-08-08 | $155.72M derived: sum of 4 quarters · filed 2017-08-08 |
| 2017-03-31 | -$25.28M 10-Q · filed 2017-05-08 | $60.62M derived: sum of 2 quarters · filed 2017-05-08 | $153.19M derived: sum of 3 quarters · filed 2017-05-08 | $172.17M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-12-31 | $85.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $178.48M derived: sum of 2 quarters · filed 2017-02-27 | $197.46M derived: sum of 3 quarters · filed 2017-08-08 | $28.02M 10-K · filed 2017-02-27 |
| 2016-09-30 | $92.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $111.55M derived: sum of 2 quarters · filed 2017-08-08 | -$57.89M 10-Q · filed 2016-11-09 | -$48.33M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-06-30 | $18.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$150.46M 10-Q · filed 2017-08-08 | -$140.90M derived: sum of 3 quarters · filed 2017-08-08 | -$150.11M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | -$169.44M 10-Q · filed 2017-05-08 | -$159.88M derived: sum of 2 quarters · filed 2017-05-08 | -$169.09M derived: sum of 3 quarters · filed 2017-05-08 | -$208.50M derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | $9.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $349.00K derived: sum of 2 quarters · filed 2017-02-27 | -$39.06M derived: sum of 3 quarters · filed 2017-02-27 | -$21.27M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$9.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$48.62M derived: sum of 2 quarters · filed 2016-11-09 | -$30.83M 10-Q · filed 2016-11-09 | -$13.48M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | -$39.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$21.62M 10-Q · filed 2016-08-09 | -$4.27M derived: sum of 3 quarters · filed 2017-02-27 | -$58.37M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $17.79M 10-Q · filed 2016-05-05 | $35.13M derived: sum of 2 quarters · filed 2017-02-27 | -$18.96M derived: sum of 3 quarters · filed 2017-02-27 | -$121.75M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $17.35M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$36.75M derived: sum of 2 quarters · filed 2017-02-27 | -$139.53M derived: sum of 3 quarters · filed 2017-02-27 | -$129.83M 10-K · filed 2017-02-27 |
| 2014-09-30 | -$54.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$156.88M derived: sum of 2 quarters · filed 2015-11-09 | -$147.18M 10-Q · filed 2015-11-09 | -$138.02M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$102.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$93.08M 10-Q · filed 2015-08-10 | -$83.92M derived: sum of 3 quarters · filed 2016-02-29 | -$68.51M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $9.70M 10-Q · filed 2015-05-07 | $18.86M derived: sum of 2 quarters · filed 2016-02-29 | $34.27M derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $9.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $24.57M derived: sum of 2 quarters · filed 2016-02-29 | $16.39M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $15.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $7.23M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | -$8.18M 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | -$32.26M 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $18.54M 10-K · filed 2014-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |